Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Dad issues urgent plea to find stem cell donor for his son- If everyone on Earth sat in the ocean at once, how much would sea level rise?
- Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover
- Purchases of iPhone 17 Pro soar across Gaza amid 'limited' humanitarian aid
- Dozens killed as Angola flood death toll rises
- Language Learning Stages: Which One Gets Your Vote?
- Tear gas and arrests: Iranian regime continues crackdown on protesters amid economic unrest
- 4K televisions for Extreme Film Watching Experience
- Hundreds of Gazans evacuated from Strip for medical treatment - COGAT
